About Kartos Therapeutics
Kartos Therapeutics is a company based in Redwood City (United States) founded in 2018 was acquired by Ipsen in June 2026. Kartos Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Redwood City, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Kartos Therapeutics
Detailed funding history for Kartos Therapeutics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Kartos Therapeutics
Kartos Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ipsen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes
|
Locked | Locked | Locked |
Investor details for Kartos Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kartos Therapeutics
Investment portfolio details for Kartos Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kartos Therapeutics
Detailed financials for Kartos Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kartos Therapeutics Comparisons
Peer comparison for Kartos Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kartos Therapeutics
Kartos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of Kartos Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kartos Therapeutics
Complete news archive for Kartos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kartos Therapeutics
Kartos Therapeutics was founded in 2018.
Kartos Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Kartos Therapeutics was founded in 2018 and is based in Redwood City, United States. Focus is placed on the biotechnology sector, where therapeutics for cancer are developed. The lead candidate, Navtemadlin (KRT-232), an oral MDM2 inhibitor, targets Myelofibrosis, Polycythemia Vera, Acute Myeloid Leukemia, and Merkel Cell Carcinoma. Operations center on advancing these treatments through clinical development.
Kartos Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
Kartos Therapeutics has 1 investor. Key investors include Ipsen.